Elsevier

Clinical Therapeutics

Volume 26, Issue 8, August 2004, Pages 1249-1260
Clinical Therapeutics

Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo-controlled trial

https://doi.org/10.1016/S0149-2918(04)80081-XGet rights and content

Abstract

Background

Valdecoxib, a cyclooxygenase (COX)-2 specific inhibitor, is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and primary dysmenorrhea. Therapeutic doses of COX-2 specific inhibitors are as effective as nonspecific nonsteroidal anti-inflammatory drugs in reducing inflammatory pain while sparing the gastrointestinal and platelet toxicity associated with nonspecific COX-1 inhibition.

Objective

The aim of this study was to assess the analgesic efficacy and tolerability of valdecoxib 40 mg/d compared with placebo in the treatment of chronic low back pain.

Methods

This 4-week, prospective, randomized, double-blind placebo-controlled, parallel-group study was conducted at 37 centers across the United States and 5 centers in Canada. Patients aged ≥18 years with chronic low back pain in flare were enrolled. Patients were randomized to receive valdecoxib 40-mg/d or placebo tablets, once daily for 4 weeks. Patients rated low back pain intensity on a visual analog scale and completed the Roland-Morris Disability Questionnaire and the modified Brief Pain Inventory—Short Form (mBPI-SF) at each visit.

Results

Two hundred ninety-three patients were enrolled. The valdecoxib group comprised 148 patients (81 women, 67 men; mean [SD] age, 48.6 [13.3] years; mean [SD] body weight, 86.6 [20.9] kg), and the placebo group included 145 patients (85 women, 60 men; mean [SD] age, 48.7 [12.6] years; mean [SD] body weight, 85.6 [19.9] kg). Of the enrolled patients, 249 completed the study: 134 patients (91%) who received valdecoxib and 115 patients (79%) who received placebo. No statistically significant differences in patient baseline characteristics were noted between treatment groups, except in response to 1 mBPI-SF question; patients in the valdecoxib group reported significantly greater interference in relations with other people due to pain than did those in the placebo group (P = 0.048). Changes from baseline in low back pain intensity were significantly greater in valdecoxib-treated patients at each assessment (all, P < 0.001 vs placebo). Pain scores on the mBPI-SF indicated significantly greater pain relief with valdecoxib at each assessment (all, P ≤ 0.014 vs placebo). Improvements in mean Roland-Morris Disability Questionnaire score with valdecoxib were significantly greater than with placebo at each assessment (all, P ≤ 0.003). Although the overall incidence of adverse events (AEs) was significantly higher among patients receiving valdecoxib than those receiving placebo (35.1% vs 24.1%, respectively; P = 0.042), no significant differences were found between groups for the incidence of any individual AE. Most AEs (89% [77/87 total events]) were mild or moderate in severity.

Conclusions

In this study of patients with chronic low back pain, valdecoxib 40 mg/d provided rapid relief (within 1 week) and consistent relief (over 4 weeks). In addition, significant improvement in function and decreased disability were found with valdecoxib compared with placebo.

References (32)

  • CamuF et al.

    Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty

    Am J Ther

    (2002)
  • van TulderMW et al.

    Nonsteroidal anti-inflammatory drugs for low back pain: A systematic review within the framework of the Cochrane Collaboration Back Review Group

    Spine

    (2000)
  • BordaIT

    The spectrum of adverse gastrointestinal effects associated with nonsteroidal anti-inflammatory drugs

  • BrooksPM et al.

    Nonsteroidal antiinflammatory drugs—differences and similarities

    N Engl J Med

    (1991)
  • SeibertK et al.

    Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain

  • MasferrerJL et al.

    Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic

  • Cited by (63)

    View all citing articles on Scopus

    The results of this study were presented in abstract and poster form at the 22nd Annual Scientific Meeting of the American Pain Society, March 20-23, 2003, Chicago, Illinois.

    View full text